Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.
Imaging Microglial/Macrophage Activation in Spinal Cords of Experimental Autoimmune Encephalomyelitis Rats by Positron Emission Tomography Using the Mitochondrial 18 kDa Translocator Protein Radioligand [18F]DPA-714.
Interferon-β and serum 25-hydroxyvitamin D interact to modulate relapse risk in MS.
Calpain inhibition attenuated morphological and molecular changes in skeletal muscle of experimental allergic encephalomyelitis rats.
Immunology 2012
The cost burden of multiple sclerosis in the United States: a systematic review of the literature.
Receptos provides update on progress of lead product candidate RPC1063
Tumefactive multiple sclerosis requiring emergent biopsy and histological investigation to confirm the diagnosis: a case report.
Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study.
A Randomized Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose Naltrexone
The investigation of acute optic neuritis: a review and proposed protocol.
Frequency of Comorbidities and Their Association with Clinical Disability and Relapse in Multiple Sclerosis.
Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial.
Optimizing parameter choice for FSL-Brain Extraction Tool (BET) on 3D T1-images in multiple sclerosis.
Long-term effects of dalfampridine in patients with multiple sclerosis.
Lodonal/LDN
Eicosapentaenoic acid (EPA) induces peroxisome proliferator-activated receptors and ameliorates experimental autoimmune encephalomyelitis.
Cyclophosphamide modulates CD4+ T cells into a T helper type 2 phenotype and reverses increased IFN-gamma production of CD8+ T cells in secondary progressive multiple sclerosis.
Inhibition of Neuronal Degenerin/Epithelial Na+ Channels by the Multiple Sclerosis Drug 4-Aminopyridine.
A phase IIa randomized clinical study testing GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients - A twelve month follow-up.
The age-range of risk of developing multiple sclerosis: evidence from a migrant population in Australia.
B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis.
[Budget impact analysis of the first-line treatment of relapsing remitting multiple sclerosis in Spain. Reply].
Santhera receives first product approval: Health Canada approves Catena® for treatment of Friedreich's ataxia
UVB light attenuates the systemic immune response in CNS autoimmunity.

Pages